With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...
While an investment in Neurocrine remains dependent on INGREZZA, the company has also received FDA approval for its new drug, CRENESSITY (crinecerfont) as of December. CRENESSITY is a treatment ...
Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...
Neurocrine’s drug has a clear advantage, however, as it has been approved without the black box warning on depression and suicidal ideation that its rival must carry. Chief executive Kevin ...
Both Guggenheim's Yatin Suneja and Wainwright's Andrew Fein were more modest in their Neurocrine price target cuts, with the former shaving $2 off his target to $163 per share and the latter reducing ...
Also Read: Neurocrine’s Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential Under the terms of the updated agreement ...
The non-GAAP net income was $173.4 million, showing improved margins due to strong sales in its drug portfolio. Neurocrine's R&D expenses increased by 35% to $185.6 million, highlighting its ...
Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by ...
Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...